Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
Simone Di Cola,Gennaro D’Amico,Paolo Caraceni,Filippo Schepis,Simone Loredana,Pietro Lampertico,Pierluigi Toniutto,Silvia Martini,Sergio Maimone,Antonio Colecchia,Gianluca Svegliati Barone,Carlo Alessandria,Alessio Aghemo,Saveria Lory Crocè,Luigi Elio Adinolfi,Maria Rendina,Lucia Lapenna,Enrico Pompili,Giacomo Zaccherini,Dario Saltini,Massimo Iavarone,Giulia Tosetti,Carolina Martelletti,Veronica Nassisi,Alberto Ferrarese,Ilaria Giovo,Chiara Masetti,Nicola Pugliese,Michele Campigotto,Riccardo Nevola,Manuela Merli,Giulia Iannone,Paola Serri,Gaetano Bertino,Clara Balsano,Nerio Iapadre,Marcello Maida,David Sacerdoti,Leonardo Antonio Natola,Carolina Ciacci,Antonella Santonicola,Raffaele Cozzolongo,Lorenzo Antonio Surace,Anna Ludovica Fracanzani,Annalisa Cespiati,Alessandro Federico,Mario Romeo,Antonio Grieco,Giuseppe Marrone,Luca Vizioli
DOI: https://doi.org/10.1016/j.jhep.2024.05.020
IF: 25.7
2024-05-23
Journal of Hepatology
Abstract:BACKGROUND AND AIM Sarcopenia and myosteatosis are common in patients with cirrhosis. This study aimed to determine the prevalence of these muscle changes, their interrelations and their prognostic impact over a 12-month period. METHODS We conducted a prospective multicentre study involving 433 patients. Sarcopenia and myosteatosis were evaluated using computed tomography scans. The 1-year cumulative incidence of relevant events was assessed by competing risk analysis. We used a Fine-Gray model adjusted for known prognostic factors, to evaluate the impact of sarcopenia and myosteatosis on mortality, hospitalization, and liver decompensation. RESULTS At enrolment, 166 patients presented with isolated myosteatosis, 36 with isolated sarcopenia, 135 with combined sarcopenia and myosteatosis and 96 patients showed no muscle changes. The 1-year cumulative incidence of death in patients with either sarcopenia and myosteatosis (13.8%) or isolated myosteatosis (13.4%) was over twice that of patients without muscle changes (5.2%) or with isolated sarcopenia (5.6%). The adjusted subhazard ratio for death in patients with muscle changes was 1.36 (95% CI 0.99, 1.86) (P=0.058). The cumulative incidence of hospitalization was significantly higher in patients with combined sarcopenia and myosteatosis than in patients without muscle changes (adjusted subhazard ratio 1.18, 95% CI 1.04 to 1.35). The cumulative incidence of liver decompensation was greater in patients with combined sarcopenia and myosteatosis (p=0.018) and those with isolated sarcopenia (p=0.046) than in patients without muscle changes. Lastly, we found a strong correlation between function tests and frailty scores with the presence of muscle changes. CONCLUSIONS Myosteatosis, whether alone or combined with sarcopenia, is highly prevalent in patients with cirrhosis and is associated with significantly worse outcomes. The prognostic role of sarcopenia should always be evaluated in relation to the presence of myosteatosis. Impact and implications This study investigates the prognostic role of muscle changes in patients with liver cirrhosis. The novelty of this study is the multicentre, prospective nature and the distinguishing impact of individual muscle changes and their combination on prognosis in cirrhosis. This study highlights the prognostic role of myosteatosis, especially when combined with sarcopenia. On the other hand, the relevance of sarcopenia could be mitigated when considered together with myosteatosis. The implication from these findings is that sarcopenia should never be evaluated individually and that myosteatosis may have a dominant role in the prognosis of patients with liver cirrhosis.
gastroenterology & hepatology